NCT06258668Recruiting
Real-World Safety and Effectiveness of Sotyktu (Deucravacitinib) in Patients With Moderate-to-Severe Plaque Psoriasis in Korea
Sotyktu (Deucravacitinib) Post-Marketing Surveillance in Korean Patients With Moderate-to-Severe Plaque Psoriasis
Source: ClinicalTrials.gov · Last updated 6 Nov 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The purpose of this observational study is to describe the safety and effectiveness of deucravacitinib in participants in Korea that have been diagnosed with moderate-to-severe plaque psoriasis.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 505 (estimated)
- First submitted
- 3 Feb 2024
- Start date
- 21 Aug 2024
- Primary completion date
- 30 Sept 2028
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Psoriasis
- NCT number
- NCT06258668
What you commit to
- Study type: Observational
- Planned participants: 505
- From 21 Aug 2024 to the primary completion date, 30 Sept 2028
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participants for whom deucravacitinib is contraindicated as clarified in Korean prescribing information by ministry of food and drug safety (MFDS)
Other
- Participants prescribed deucravacitinib for therapeutic indications not approved in Korea
Who the study is looking for
- Adult participants ≥19 years of age
- Diagnosis of moderate-to-severe plaque psoriasis
- Candidate for phototherapy or systemic therapy
- Will begin deucravacitinib according to approved product label
Age in the registry: 19 years to - · Sex: All
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Novotech Laboratory Korea Co., Ltd. Coordinator of this site? Confirm its status | Seoul | South Korea | Recruiting |
| Local Institution - 0001 Coordinator of this site? Confirm its status | Seoul | South Korea | Withdrawn |
This page is information, not medical advice. Discuss any trial with your doctor.